(Q38105454)

28 August 2017

title

Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs (English)

1 reference

28 August 2017

1

1 reference

28 August 2017

Samuel M Meier

3

0 references

Michael Groessl

object named as

Michael Groessl

series ordinal

2

0 references

Angela Casini

object named as

Angela Casini

series ordinal

4

0 references

Paul Dyson

object named as

Paul J Dyson

series ordinal

5

0 references

publication date

1 July 2013

1 reference

28 August 2017

published in

Chemical Society Reviews

1 reference

28 August 2017

volume

42

1 reference

28 August 2017

issue

14

1 reference

28 August 2017

page(s)

6186-6199

1 reference

Metal-based antitumour drugs in the post genomic era.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Antitumour metal compounds: more than theme and variations

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Direct cellular responses to platinum-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Carbohydrate-metal complexes and their potential as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Bioorganometallic chemistry--from teaching paradigms to medicinal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Molecular mechanisms and proposed targets for selected anticancer gold compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Organometallic anticancer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Targeting proteins with metal complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Mass spectrometry in bioinorganic analytical chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Improving protein identification using complementary fragmentation techniques in fourier transform mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Interactions of platinum(II) complexes with sulfur-containing peptides studied by electrospray ionization mass spectrometry and tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Tandem mass spectrometry for characterization of covalent adducts of DNA with anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Large-scale analysis of the yeast proteome by multidimensional protein identification technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Elemental bioimaging in kidney by LA-ICP-MS as a tool to study nephrotoxicity and renal protective strategies in cisplatin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Laser ablation ICP-MS for quantitative biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Matrix-assisted laser desorption/ionization imaging mass spectrometry of oxaliplatin derivatives in heated intraoperative chemotherapy (HIPEC)-like treated rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

An automated multidimensional protein identification technology for shotgun proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Implications for drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

A mass spectrometric and molecular modelling study of cisplatin binding to transferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Kinetic analysis of the reaction between d(TTGGCCAA) and [Pt(NH3)3(H2O)]2+ by enzymatic degradation of the products and ESI and MALDI mass spectrometries

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Cisplatin-protein adducts are efficiently removed by glutathione but not by 5'-guanosine monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Ligand effects on the binding of cis- and trans-[PtCl(2)Am(1)Am(2)] to proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Direct determination of the primary binding site of cisplatin on cytochrome C by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Probing the interaction of cisplatin with cytochrome C by electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Use of top-down and bottom-up Fourier transform ion cyclotron resonance mass spectrometry for mapping calmodulin sites modified by platinum anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Mass spectrometric studies of cisplatin-induced changes of hemoglobin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Platination of superoxide dismutase with cisplatin: tracking the ammonia ligands using Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Novel insights into the bottom-up mass spectrometry proteomics approach for the characterization of Pt-binding proteins: The insulin-cisplatin case study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Interaction of cisplatin with methionine- and histidine-containing peptides: competition between backbone binding, macrochelation and peptide cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

The influence of methionine-containing peptides on the reaction of carboplatin with 5′-guanosine monophosphate: a comparison with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Analytical methodologies for the determination of cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Bioanalytical and biophysical techniques for the elucidation of the mode of action of metal-based drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Electrospray ionization mass spectrometric study of purine base-cisplatin complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

CE in anticancer metallodrug research--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5'-monophosphate O6-N7 chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Mass spectrometric analysis of ubiquitin–platinum interactions of leading anticancer drugs: MALDI versus ESI

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

Reaction of Zn7Metallothionein withcis- andtrans-[Pt(N-donor)2Cl2] Anticancer Complexes: trans-PtIIComplexes Retain Their N-Donor Ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3CS35532B

21 January 2018

Identifiers

DOI

10.1039/C3CS35532B

1 reference

28 August 2017

1 reference